Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Analyzing the findings of the SERENA-6 trial and its implications in the clinic

Michael Gnant • 2 Jun 2025
ASCO 2025
Breast Cancer Camizestrant
SERENA-6

Michael Gnant, MD, FACS, Medical University of Vienna, Vienna, Austria, comments on the Phase III SERENA-6 trial (NCT04964934) of camizestrant with CDK4/6 inhibitors during first-line endocrine-based therapy in HR+/HER2- breast cancer. The trial showed the benefits of using circulating tumor ctDNA (ctDNA) to guide treatment changes. However, unanswered questions remain in terms of overall survival benefit and financial toxicity concerns. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Gnant

Tailoring endocrine therapy: risk-based strategies and symptom management in HR+ breast cancer
6:03
Tailoring endocrine therapy: risk-based strategies and symptom management in HR+ breast cancer
Michael Gnant • 31 May 2025
What is the role of CDK4/6 inhibitors in early breast cancer?
5:07
What is the role of CDK4/6 inhibitors in early breast cancer?
Michael Gnant • 6 Jun 2023
NeoALTTO: HER2/CEP17 ratio as a predictive biomarker in HER+ breast cancer
2:27
NeoALTTO: HER2/CEP17 ratio as a predictive biomarker in HER+ breast cancer
Michael Gnant • 8 Jun 2023
Late recurrences in ER-positive breast cancer and the challenges it poses for treatment
7:05
Late recurrences in ER-positive breast cancer and the challenges it poses for treatment
Michael Gnant • 8 Jun 2023

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals